同类氨酸,心血管风险和死亡率
Winfried März1, Andreas Meinitzer, Christiane Drechsler
1Clinical Institute of Medical and Chemical Laboratory Diagnostics, Division of Endocrinology and Nuclear Medicine, Medical University of Graz, Graz, Austria.
Circulation
|August 25, 2010
概括
低水平的homoarginine与心血管疾病的增加和冠状动脉血管学和血液透析的患者的整体死亡率有关. 这突出了homoarginine作为心血管风险的潜在生物标志物.
科学领域:
- 心血管医学 心血管医学
- 生物化学 生物化学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 氨基酸衍生物homoarginine可能会影响氧化的可用性和内皮功能.
- 同素水平对心血管结果和死亡率的影响在很大程度上是未知的.
研究的目的:
- 调查同类氨酸水平与心血管和全因死亡率之间的关联.
- 探索homoarginine,功能和内皮功能障碍标志物之间的关系.
主要方法:
- 根据两个队列中的同质氨酸水平评估死亡风险:来自LURIC研究的3305名患者 (冠状动脉血管学) 和来自4D研究的1244名患者 (血液透析).
- 分析了与估计的膜过率和粘附分子 (ICAM-1,VCAM-1) 的关联.
主要成果:
- 在LURIC研究中,同类氨酸的最低四分位数 (<1.85μmol/L) 与最高四分位数 (>3.1μmol/L) 相比,心血管死亡率高出4倍.
- 较低的homoarginine水平与功能受损以及较高水平的内皮功能障碍标志物相关.
- 血液透析患者 (4D研究) 的平均同质氨酸水平较低 (<0.87μmol/L),与水平较高 (>1.4μmol/L) 的患者相比,死亡风险增加了2倍.
结论:
- 在接受冠状动脉血管学和血液透析的患者中,同类氨酸水平与心血管和全因死亡率独立相关.
- 需要进行进一步的研究,以了解同类氨酸与死亡率相关的潜在机制.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:16Antianginal Drugs: Nitrates and β-Blockers
1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
769
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
769
01:30Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
01:30Heart Failure V: Medical Management
642
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
642
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747